Media Coverage

How can early-phase CROs stay afloat in a changing market?

08/19/2013

With fewer and fewer early-stage molecules moving through pipelines, CROs that used to count on early-phase business are having to get creative. For Charles River Laboratories, the key to success in an evolving market is delivering consistent quality.

Charles River to Add More Rat Models as Part of Discovery Push

07/30/2013

Charles River Laboratories will add four new rat models to its drug discovery services which will provide more objective endpoints for companies developing pain medications, as well as those looking for a higher translation between discovery and first-in-human studies.


Artifacts of Virus Filter Validation

05/06/2013

Virus filters are used in biomanufacturing to ensure the safety of biopharmaceutical drug products. As part of filter implementation, manufacturers are required to validate that the filtration process can indeed remove virus.

Big pharma has lost its way

05/03/2013

If you want to do basic research to develop all new molecules to conquer diseases that can't easily be conquered, chances are you'll have to hire Charles River Laboratories to do the testing. This company can do it faster and more cheaply than anyone else can. It is the acknowledged leader, and no one can dispute that.

Executive Profile - Jim Foster

05/03/2013

Like many kids, Jim Foster helped out his father by putting in shifts at the family business while he was in junior high and high school. But when your father is Henry Foster, founder of Wilmington-based Charles River Laboratories, that classic childhood work experience involves cleaning the cages of lab animals - and even assisting with veterinary surgeries.

James Foster Interview on Mad Money with Jim Cramer

05/02/2013

Mad Money host Jim Cramer recently interviewed Charles River CEO James Foster. In this interview, James Foster discusses Charles River's quarter, the impact from the sequester and the role Charles River plays in helping companies move their drugs into the pipeline.

Working Partnerships

02/13/2013

Today’s tough challenges are forcing change in the pharmaceutical industry. Pharma talks to several service providers to discover how these changes are reshaping their business strategies and fortifying their alliances with pharma companies.

5 Reasons to Use OCT in Preclinical Studies

01/28/2013

Optical coherence tomography (OCT) is a noninvasive imaging technology that allows for a cross-sectional view of the retina, the retinal-vitreal interface, and anterior ocular structures at near-cellular resolution. In the clinic it is used to diagnose and follow ocular degenerative diseases, but in preclinical studies it can be used to help evaluate pharmacological or toxicological drug effects.

Fighting Cancer: Better Models Make Better Drugs

01/23/2013

We know that comparing man-to-animal will never be a perfect science. There's always room to improve the chances of a successful transition from bench to bedside. Doing so requires more precise techniques that produce better clinical outcomes. So, how do we improve preclinical animal research such that the tumors being tested in animal models more closely resemble those that will be found in human patients?

Displaying results 1-10 (of 31)
 |<  < 1 - 2 - 3 - 4  >  >|